Results 271 to 280 of about 5,838,181 (363)

Complications in a Patient With Multiple Myeloma Mimicking Bronchopneumonia. [PDF]

Cureus
Gowda A, Guruswamy P, Shyllesh H A, Kumar TN.   +3 more
europepmc   +1 more source

Vildagliptin and Omarigliptin Differentially Bind to DPP‐4 Homodimers and Modulate Osteoclast‐Mediated Bone Resorption

Comprehensive Physiology, Volume 16, Issue 1, February 2026.
Vildagliptin and omarigliptin, dipeptidyl peptidase‐4 (DPP‐4) inhibitors, have differential effects on bone cells. Although vildagliptin improved the bone microstructure of high‐fat diet‐fed rats, it was unable to downregulate osteoclastogenesis or the expression of key osteoclast transcripts.
Ratchaneevan Aeimlapa, Jiraporn Panmanee, Jarinthorn Teerapornpuntakit, Kannikar Wongdee, Jirawan Thongbunchoo, Nattapon Panupinthu, Saovaros Svasti, Nattayaporn Apaijai, Piangkwan Sa‐nguanmoo, Siriporn Chattipakorn, Nipon Chattipakorn, Narattaphol Charoenphandhu   +11 more
wiley   +1 more source

Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection. [PDF]

Blood Adv
Sudha P, Pham P, Niu W, Liu E, Wang L, Truong G, Ligocki C, Al-Azzawi R, Surapenini M, Bray SM, Vetrini F, Czader M, Tayeh MK, Lee K, Abonour R, Suvannasankha A, Walker BA.   +16 more
europepmc   +1 more source

Single‐cell sequencing for cancer precision medicine: From mechanism discovery to diagnosis and therapeutics

Clinical and Translational Discovery, Volume 6, Issue 1, February 2026.
Single‐cell sequencing overcomes bulk sequencing limitations, enabling high‐resolution multi‐omics analysis at the single‐cell level. It reveals tumour heterogeneity, identifying key subpopulations and tumour microenvironment interactions driving progression and resistance.
Yue Zhao, Hancong Li, Huanzuo Yang, Gongshuang Zhang, Xinyue Fu, Peiheng Li, Puxing He, Shuang Wu, Han Luo   +8 more
wiley   +1 more source

Cystoid Macular Edema as Manifestation of Smoldering Multiple Myeloma: A Case Report. [PDF]

J Vitreoretin Dis
Pandiri S, Meshkin RS, Chaaya C, Dorsey HG, Hoyek S, Zekavat SM, Patel NA.   +6 more
europepmc   +1 more source

Beyond bacterial defences: the role of lysozyme in cancer

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
Lysozyme (LYZ) is a multi‐functional secreted factor that encompasses both antibacterial and immunomodulatory functions. Emerging evidence highlights its complex role in tumour progression by directly influencing tumour cells and modulating the immune microenvironment.
Lei Wang, Qian Dong, Fuchu He, Zhiwen Gu, Aihua Sun   +4 more
wiley   +1 more source

Daratumumab-based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study. [PDF]

Hemasphere
Beksac M, Fıratlı Tuglular T, Gay F, Mina R, Katodritou E, Unal A, Cavo M, Ozsan GH, van der Velden VHJ, Beverloo BH, Vermeulen M, van Duin M, Seval GC, Sevindik OG, Merante S, Manousou K, Sonneveld P, Zamagni E, Terpos E.   +18 more
europepmc   +1 more source

Tofacitinib‐Induced Weight Gain in Context: comment on the article by Wollenhaupt et al.

ACR Open Rheumatology, Volume 8, Issue 2, February 2026.
Andriko Palmowski, Frank Buttgereit, David Simon, Arnd Kleyer, Norman Michael Drzeniek   +4 more
wiley   +1 more source

Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley   +1 more source